Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0084 • ACR Convergence 2024
DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
Xi Li, bing Li, Jun Yao, bin zhang, zhongyuan zhu, yang Qiu and haiqing Hua, Duality Biologics Ltd, Shanghai, China (People's Republic)
Background/Purpose: BDCA2 (blood dendritic cell antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), whose over-production of type I interferon (IFN-I) is crucial in…
Abstract Number: 0130 • ACR Convergence 2024
Depression Genetic Risk, Diagnoses, and Treatments in Association with Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program
Jing Cui¹, Jeong Yee¹, Emily Oakes¹, Elizabeth Karlson¹, Leah Santacroce¹, Hongshu Guan¹, Laura D. Kubzansky², Karestan C. Koenen², Candace Feldman¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Diagnoses of depression, highly prevalent in SLE and RA populations, were associated with increased cardiovascular disease (CVD) risk in the All of Us Research…
Abstract Number: 0183 • ACR Convergence 2024
Sensitivity of 2019 EULAR/ACR SLE Criteria and Initial Organ Manifestations for Black and Hispanic Children with Juvenile Systemic Lupus Erythematosus (jSLE) at a Large Tertiary Care Center
Michelle Butts¹, Emily Beil¹, Danielle Guffey², Andrea Ramirez¹, Cagri Yildirim-Toruner³, Erin Peckham-Gregory¹ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disorder with diverse features, posing classification challenges. In 2019, EULAR and ACR developed new classification criteria to…
Abstract Number: 0241 • ACR Convergence 2024
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Rebecca Sadun¹, Dan Crair¹, Emmanuel Walter¹, Eugene St.Clair², David Pisetsky², Amanda Eudy³, Megan Clowse⁴, Jennifer Rogers⁵, Kai Sun¹, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss¹, Sarah Valencia¹ and M. Athony Moody⁷, ¹Duke University, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Duke University, Raleigh, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University School of Medicine, Durham
Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
Abstract Number: 0430 • ACR Convergence 2024
Clues from Early Gestational Mean Arterial Pressure in Predicting Preeclampsia Risk in Systemic Lupus Erythematosus (SLE)
Rashmi Dhital¹, Dilli Poudel² and Ukachi Emeruwa³, ¹UC San Diego, Brentwood, TN, ²Vanderbilt University, Nashville, TN, Brentwood, TN, ³UC San Diego, San Diego
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a known risk factor for chronic hypertension (cHTN) as well as preeclampsia. While the role of cHTN is known,…
Abstract Number: 0612 • ACR Convergence 2024
Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
Nevin Hammam¹, Ahmed Elsaman², Esam Abualfadl³, Soha Senara⁴, Nada M. Gamal⁵, Mona H. Abd Elsamea⁵, Abdelhfeez Moshrif⁶, Samar Tharwat⁷, Osman Hammam⁸ and Tamer A Gheita⁹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; Qena/Luxor Hospitals, Qena, Egypt, Sohag, Egypt, ⁴Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Assiut, Egypt, ⁶Al-azhar university, Assiut, Egypt, ⁷Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁸Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a great heterogeneity and unpredictable flare. In managing patients with SLE, the diagnosis…
Abstract Number: 0630 • ACR Convergence 2024
Lupus Lymphocyte Activation Score of Pathologic T and B Cell Phenotypes Increased in Patients at Risk of Systemic Lupus Erythematosus
Alice Horisberger¹, Ifeoluwakiisi Adejorin², Julia Caldropoli³, Eilish Dillon⁴, Emily Oakes⁵, Kathryne Marks⁵, Takanori Sasaki⁶, Karen Costenbader⁷ and Deepak Rao⁴, ¹Brigham and Woman's Hospital, Harvard Medical School, Lausanne, Switzerland, ²Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, Switzerland, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: In systemic lupus erythematosus (SLE), loss of self-tolerance and pathologic T and B cell interactions lead to autoantibodies against nuclear antigens (ANA) production. In…
Abstract Number: 0649 • ACR Convergence 2024
Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Yeo-Jin Lee¹, Eun-Ju Lee², Minji Kim³, Mi-Ra Cho⁴, Soo Min Ahn³, Seokchan Hong⁴, Ji Seon Oh⁴, Chang-Keun Lee⁴, Bin Yoo⁴ and Yong-Gil Kim³, ¹Asan medical center, Seoul, South Korea, ²Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ⁴Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multi-organ systems, particularly the kidneys. Urine is an ideal source of SLE biomarkers…
Abstract Number: 0667 • ACR Convergence 2024
Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry
Takehiro HIrayama¹, Kohei Tsujimoto², Kayoko Kaneko³, Sakiko Isojima⁴, Kunihiro Ichinose⁵, Yasunori Iwata⁶, Kenji Oku⁷, Kenei Sada⁸, Yoshiya Tanaka⁹, Ayako Nakajima¹⁰, Keishi Fujio¹¹, Masakazu Matsushita¹², Takako Miyamae¹³, Atsuko Murashima³ and Atsushi Kumanogoh¹⁴, ¹Osaka university, Ibaraki City, Japan, ²Osaka University, Toyonaka, Osaka, Osaka, Japan, ³National Center for Child Health and Development, Setagaya, Tokyo, Japan, ⁴Showa Univeristy, Shinagawa, Tokyo, Japan, ⁵Shimane University, Izumo, Shimane, Japan, ⁶Kanazawa University, kanazawa, Japan, ⁷Kitazato University, Sagamihara, Kanagawa, Japan, ⁸Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan, ¹¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., TOKYO, Japan, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Osaka University, Osaka, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse clinical manifestations and organ involvement, posing significant challenges in its management. The emergence…
Abstract Number: 0832 • ACR Convergence 2024
Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs
Sarah McCuaig¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 0998 • ACR Convergence 2024
Trends and Disparities in Cardiovascular Deaths in Systemic Lupus Erythematosus: A Population-Based Retrospective Study in the United States from 1999 to 2021
Faizan Ahmed¹, Shreyas Patil², Yash Deshpande³, Simran Bhimani³, Anand Maligireddy⁴, Leighton Hope⁵, Tehmasp Rehman Mirza⁶, Mohamed Abugrin⁷, Hardik Valand⁸, Chaitanya Rojulpote⁵ and karthik Gonuguntla⁹, ¹Ameer-ud-Din Medical College, Lahore, Pakistan, ²The Wright Center, Scranton, ³The Wright Center for Graduate Medical Education, Scranton, PA, ⁴The Wright Center, GME, Scranton, PA, ⁵Saint Louis University, St. Louis, MO, ⁶Department of Internal Medicine, Shalamar Medical and Dental College, Lahore, ⁷Bassett Medical Center, Cooperstown, ⁸Trinity Health System, Steubenville, OH, ⁹West Virginia University, Morgantown
Background/Purpose: This study aimed to analyze two decades of consecutive mortality data to investigate cardiovascular deaths in Systemic Lupus Erythematosus (SLE) across the United States…
Abstract Number: 1242 • ACR Convergence 2024
Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms
Joseph F. Merola¹, Victoria Werth², Jiyoon C. Choi³, Brandon Becker³, Teresa Edwards⁴, Coburn Hobar⁵, Samantha Pomponi⁵ and Vibeke Strand⁶, ¹UT Southwestern Medical Center, Dallas, TX, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³Bristol Myers Squibb, Princeton, ⁴RTI International, Research Triangle Park, NC, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that disproportionately impacts women of childbearing age. Although the incidence varies widely based on ethnic…
Abstract Number: 1279 • ACR Convergence 2024
Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes
Ekemini Ogbu¹, Jareen Meinzen-Derr², Michael Wagner², Rashmi Sahay², Dhriti Sharma², J Michael Taylor², Sudhakar Vadivelu³, Mekibib Altaye² and hermine brunner¹, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Cerebrovascular accidents (CVA) are one of the most devastating neurologic manifestations of childhood-onset systemic lupus erythematosus (cSLE). The spectrum of CVA in cSLE (CVAcSLE)…
Abstract Number: 1494 • ACR Convergence 2024
Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Ioannis Parodis¹, Julius Lindblom², Alexandre Tsoi³, Dionysis Nikolopoulos⁴ and Lorenzo Beretta⁵, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: The efficacy of belimumab in treating SLE has been demonstrated in several phase 3 randomized clinical trials (RCTs). These trials showed belimumab efficacy on…
Abstract Number: 1510 • ACR Convergence 2024
Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
Romina Nieto¹, Rosana Quintana², Diana Carolina Fernández Ávila³, Rosa Serrano Morales⁴, Guillermina Harvey⁵, Lucia Hernandez⁶, Karen Roberts⁷, Nidia Meras⁸, Cintia Otaduy⁹, Elisa Novatti¹⁰, Valeria Arturi¹¹, Erika S. Palacios Santillan⁷, Boris Kisluk¹², Luciana González Lucero¹³, Eduardo Kerzberg¹⁴, Nicolás Pérez¹⁵, Cecilia Pisoni¹⁶, Paola Pirruccio¹⁷, María E. Crespo¹⁸, Ana Carolina Montandon¹⁹, Andrese A. Gasparin²⁰, Angela Duarte²¹, Laissa C. Alves Alvino²², Eloisa Bonfa²³, Emily Figuereido Neves²⁴, Lucas Victoria De Oliveira Martins²⁵, Iris Guerra²⁶, Milena Mimica Davet²⁷, Lizeth De La Hoz Rueda²⁸, Andrés Cadena Bonfanti²⁸, Roberth Rivera²⁹, Paola Coral Alvarado³⁰, John Fredy Jaramillo³¹, José Martínez³², Mario Moreno³³, Reyna E. Sánchez Briones³⁴, Mario Pérez Cristóbal³⁵, Eduardo Martin Nares³⁶, Yaneli Juárez-Vicuña³⁷, Yelitza González Bello³⁸, Octavio González³⁹, Leonardo R. Aguilar Rivera⁴⁰, Margarita Duarte⁴¹, Patricia Langjarth⁴², Wilkerson Pérez Medina⁴¹, Armando Calvo⁴³, Teresandris Polanco⁴⁴, Carina Pizzarossa⁴⁵, Gonzalo Silveira⁴⁶, Cristina Reategui⁴⁷, Graciela Alarcon⁴⁸, Urbano Sbarigia⁴⁹, Federico Zazzetti⁵⁰, Ashley Orillion⁵¹, Guillermo Pons-Estel⁵² and Bernardo Pons-Estel⁵², ¹Centro Regional de Enfermedades Autoinmunes y Reumaticas. GO-CREAR, Rosario, Santa Fe, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁴Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumaticas del Grupo Oroao., Rosario, Argentina, ⁵Escuela de Estadística, Facultad de Ciencias Económicas y Estadística, Universidad Nacional de Rosario, Rosario, Argentina, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), ROSARIO, Santa Fe, Argentina, ⁷Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Italiano de Córdoba, Córdoba, Spain, ⁹Hospital Córdoba, Cordoba, Spain, ¹⁰Hospital Privado Universitario de Córdoba, Córdoba, Spain, ¹¹Hospital HIGA San Martín, La Plata, Argentina, ¹²Unidad de Enfermedades Autoinmunes, Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, ¹³Hospital Padilla, Tucumán, Argentina, ¹⁴Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹⁵Instituto de Investigaciones Médicos Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, ¹⁶CEMIC, Buenos Aires, Argentina, ¹⁷Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, ¹⁸Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital das Clinicas, Universidad Federal de Goias, Goias, Brazil, ²⁰Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²¹Universidad Federal de Pernambuco, Pernambuco, Brazil, ²²Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ²³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²⁴Hospital da Clinicas de Sao Paulo, São Paulo, SP, Brazil, ²⁵Universidad Federal São Paulo, São Paulo, SP, Brazil, ²⁶Sección de Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ²⁷Facultad de Medicina y Ciencia, Universidad, San Sebastián, Chile, ²⁸Universidad Simon Bolivar, Barranquilla, Colombia, ²⁹Fundación Valle del Lili, Unidad de Reumatología, Cali, Colombia, ³⁰Facultad de Medicina, Universidad Nacional de Colombia. Hospital Universitario Nacional, Bogotá, Colombia, ³¹Centro de Referencia en Osteoporosis & Reumatología, Bogotá, Colombia, ³²Rheumatology Service, Luís Vernaza Hospital, Guayaquil, Ecuador, ³³Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, Guayaquil, Ecuador, ³⁴División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, ³⁵Centro Médico Nacional Siglo XXI, CDMX, Mexico, IMMS, Mexico, ³⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³⁷Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, CDMX, Mexico, ³⁸Depto. de Inmunología y Reumatología, Hospital General de Occidente y Universidad de Guadalajara, Guadalajara, Mexico, ³⁹Hospital Central Dr. Ignacio Morones Prieto, SLP, Mexico, ⁴⁰Servicio de Reumatología (CEAR). Hospital Universitario "Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico, ⁴¹Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴²Hospital de Clínicas I, Asunción, Paraguay, ⁴³Hospital Cayetano Heredia, San Martin de Porres, Peru, ⁴⁴Hospital Docente Padre Billini, Santo Domingo, Dominica, ⁴⁵Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁶Grupo de Investigación de EAIS y Reumatológicas, Montevideo, Uruguay, ⁴⁷Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁴⁸The University of Alabama at Birmingham, Birmingham, AL, ⁴⁹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁵⁰Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵¹Johnson & Johnson Innovative Medicine, Spring House, PA, PA, ⁵²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina
Background/Purpose: To evaluate health-related quality of life (HRQoL) in patients with active lupus nephritis (LN) at baseline and 12 months after treatment in relationship to…

« Previous Page
1
…
5
6
7
8
9
…
150
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].